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SI Presentation
Yanki Yarman

Aim

Hypothesis

• Single cell RNA sequencing data
from NASH livers from mice can be
used to visualize clusters of cell
types on a “3D map” and reveal
which of those play the most
significant role in NASH
pathogenesis.
• Our hypothesis is that specific cell
populations in the liver undergo
genetic reprogramming to handle
the molecular stresses of the
“NASH” disease state.

Single cell RNA seq data from
mouse livers (6 datasets ~2400
cells, ~12000 genetic markers: 3
control + 3 NASH livers)

Multivariate analysis of genetic
markers using R programming and
the Seurat package on “Data
Integration and Label Transfer”

Steps will be presented with the
results on the following slides

Methods

Results

After removing unwanted cells from the
dataset, the next step is to normalize the data.
“LogNormalize” normalizes the feature
expression measurements for each cell
“FindVariableFeatures” to calculate a subset of
features (1000 features for each of the two
datasets)
Linear transformation (“scaling”, mean is 0,
variance is 1) before moving on to dimensional
reduction techniques like PCA, CCA, tSNE

• Dimensional reduction techniques:
• PCA: Next we perform PCA on the scaled
data (primary component analysis)
Input: variable features, output: a graph
that shows sources of heterogeneity
• CCA: Canonical correlation analysis (CCA)
measures the association between two
sets of multidimensional variables (the
control and NASH datasets with their
variable features).

• Non-linear
dimensional reduction
techniques, such as
tSNE and UMAP place
similar cells together in
low-dimensional space
by taking into account
the first 25 most
variable features. In
the second graph, we
find “neighboring” cell
types according to the
overlap in their “25
most variable
features”.

Final graph- “Labeled cell clusters
on 3D map of hepatic gene
expression”
• Supplementary figures and tables in the
paper gave us ample information on which
hepatic cell types are associated with which
gene markers.
• To label our data, we matched the top-most
differentially expressed gene in each our 13 cell
clusters with a cell type

• The six datasets we started with have
demonstrated that there are 13 cell types
that play a role in NASH pathogenesis at
varying degrees.
• The top two of importance to us are Tcells and dendritic cells and the most
differentially expressed genetic markers
for them are Trbc2 and Cst3

Conclusion

• Analyze more datasets in NASH, crossanalyze genetic markers
• Find gene expression trends in hepatocyte
re-distribution and re-programming in
NASH pathogenesis
• Model these trends using algorithms to
predict disease course
• Ultimately, narrow down genetic targets
for pharmacotherapy to either slow down
the progression of disease or cure the
disease altogether

Future
Directions

Sources

